The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
Abstract
Selective inhibition of BCL-X L synergizes with docetaxel to inhibit the growth of solid tumors but does not inhibit granulopoiesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The use of Bcl-xl inhibitors as senolytics is largely limited by their on-target and dose-limiting platelet toxicity.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [25]
In the citing paper
“Bcl-xl inhibition with ABT263 and other small molecular inhibitors induces platelet apoptosis and results in severe thrombocytopenia, which prevents the use of ABT263 and other Bcl-xl specific inhibitors in the clinic—even for cancer patients—because platelets solely depend on Bcl-xl for survival24–27.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [25]
In the citing paper
“As reported, ABT263 was highly toxic to both WI38 IR-SCs (Fig. 1g, middle panel) and platelets16–18,24–27 (Fig. 1g, right panel; Supplementary Fig. 2).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [25]
In the citing paper
“Because both SCs and platelets, but not NCs, are primarily dependent on Bcl-xl for survival16–18,24–27 (Supplementary Fig. 1h), we evaluated the effects of PZ compared with ABT263 on the viability of WI38 NCs (Fig. 1g, left panel), IR-SCs (Fig. 1g, middle panel), and platelets (Fig. 1g, right panel).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [25]
In the citing paper
“Therefore, PZ can selectively induce apoptosis in SCs, but not platelets, which are dependent on Bcl-xl for survival while having minimal toxicity to NCs that are less sensitive to Bcl-xl inhibition than SCs16–18,24–27.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [25]
In the citing paper
“The inability of PZ to efficiently induce Bcl-2 degradation may provide additional advantages for using PROTAC technology to reduce ABT263 on-target toxicity because Bcl-2 inhibition with a high dose or an intensive treatment regimen of ABT263 can lead to neutropenia and lymphocytopenia25.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [25]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407
Self-citationControl of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Self-citationClinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Self-citationNovack, D. V., Sorenson, C. M., Shutter, J. R., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)80065-m · Cited by 1,637
Chipuk, J. E., Moldoveanu, T., Llambi, F., Parsons, M. J., & Green, D. R. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.025 · Cited by 1,476
Certo, M. V., Moore, V. D. G., Nishino, M., Wei, G., Korsmeyer, S. J., Armstrong, S. A., & Letai, A. G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.027 · Cited by 1,278
van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,271
Cited by
Sorted by citations
Items 501–548 of 548
Pan‐Hammarström, Q., & Zhang, B. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732320295.793542024
Lysosomal TMEM9-LAMTOR4-controlled mTOR signaling integrity is required for mammary tumorigenesisPreprint
Park, J., Zhang, S., Lee, S. H., Nie, L., Huang, Y., Zou, G., Jung, Y., Jun, S., Zhang, J., Lien, E. M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1546520/v1
Self-citationFu, Y., Jia, X., Yuan, J., Yu, Q., & Wang, T. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4093293
Sela, Y., Li, J., Maheswaran, S., Norgard, R. J., Yuan, S., Hubbi, M. E., Doepner, M., Xu, J. P., Ho, E. S., Mesaros, C., et al. (2023) · doi:10.1158/0008-5472.c.6513802.v1
Leto, S. M., Ferri, M., Sassi, F. P., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · doi:10.1158/1078-0432.c.6533128.v1
Whittle, J. R. R., Vaillant, F., Surgenor, E. E., Policheni, A. N., Giner, G., Capaldo, B. D., Chen, H., Liu, H. K., Dekkers, J. F., Sachs, N., et al. (2023) · doi:10.1158/1078-0432.22475475.v1
Whittle, J. R. R., Vaillant, F., Surgenor, E. E., Policheni, A. N., Giner, G., Capaldo, B. D., Chen, H., Liu, H. K., Dekkers, J. F., Sachs, N., et al. (2023) · doi:10.1158/1078-0432.22475475
Clinical Experience with Pro‐Apoptotic Agents
Lew, T. E., & Seymour, J. F. (2023) · Wiley eBooks · doi:10.1002/9781119819950.ch12
The Role of BCL-2/MCL-1 Targeting in Acute Myeloid Leukemia
Tang, K., & Chan, S. M. (2023) · Springer eBooks · doi:10.1007/978-981-99-3810-0_10
Proinflammatory cytokines sensitise mesenchymal stromal cells to apoptosisPreprint
Heng, T. S. P., Payne, N. L., Pang, S. H. M., Freeman, A. J., Ozkocak, D. C., Wallis, G., Zheng, D., Mendonca, S., O’Reilly, L. A., Gray, D. H. D., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4651490/v1
Apoptosis Resistance in Solid Tumours: A Potential Therapeutic Target in Gastric Carcinoma?
Butterworth, W. A., Griffiths, E. A., & Shannon-Lowe, C. D. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_320
Understanding and tackling the resistance to BH3-mimetics in diffuse large B-Cell lymphoma
Yildirim, N. (2024) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.88346
Li, Z., Wang, S., Yang, Z., Yang, F., Tan, J., Wei, Y., Gabazza, E. C., Santarpía, M., Wu, Y., Jiang, G., et al. (2025) · Translational Lung Cancer Research · doi:10.21037/tlcr-2025-474
Benedi, A., Beltrán‐Visiedo, M., Jiménez‐Alduán, N., del Valle, A. S., Anel, A., Naval, J., & Marzo, I. (2025) · Cancers · doi:10.3390/cancers17142290 · Cited by 2
BH3 mimetic therapies for CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia
Capdevielle, C., St-Amand, S., Neault, M., Gruber, T. A., Cellot, S., & Mallette, F. A. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.09.006
Kanwar, N., Kumar, A. H. S., Gupta, N., Gagneja, G., & Kanwal, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33343-9.00008-9
Müller, D., Mazzeo, P., Koch, R., Bösherz, M.-S., Welter, S., von Hammerstein-Equord, A. F., Hinterthaner, M., Cordes, L., Belharazem, D., Marx, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17020815
Müller, D., Mazzeo, P., Koch, R., Bösherz, M.-S., Welter, S., von Hammerstein-Equord, A. F., Hinterthaner, M., Cordes, L., Belharazem, D., Marx, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17020809
Wu, Q., Li, R., Wang, Q.-X., Zhang, M.-Y., Liu, T.-T., & Qu, Y.-Q. (2022) · Figshare · doi:10.6084/m9.figshare.20024749
Abuaita, B. H., Sharma, A. P., Heffernan, L. M., Mayandi, V., Jois, S. D. S., & Beavers, W. N. (2025) · Research Square · doi:10.21203/rs.3.rs-8361540/v1
Ochiiwa, H., Wakasa, T., Kataoka, Y., Ando, K., Oki, E., Maehara, Y., Iimori, M., & Kitao, H. (2026) · Cancer Science · doi:10.1111/cas.70329 · Cited by 1
The combination therapy with venetoclax in therapeutic strategy of acute lymphoblastic leukemia
Shamahmood, M. N., Yousefi, M. J., Miri, A., & Mezginejad, F. (2026) · Discover Oncology · doi:10.1007/s12672-026-04593-1
Advances in Metal‐Catalyzed Buchwald–Hartwig Coupling for Bioactive Molecule Synthesis: A Review
Waqas, M., Afzal, U., Abbas, H., Kanwal, A., Rasool, N., Nazir, S., Arshad, M., & Imran, M. (2026) · ChemistrySelect · doi:10.1002/slct.202507465
Lucas, C., Basabrain, A., Austin, G., Holcroft, A., Apperley, J. F., Clark, R. E., & Varadarajan, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27072991
Bcl-xL blockade targets neutrophils and synergizes with chemotherapy in lung squamous cell carcinoma
Mayet, A., Parma, B., Lécuyer, D., Defruit, A., Rana, S., Bodac, A., Demetter, P., Denanglaire, S., Ireland, A. S., Brandão, M., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00401-z
Régulation de la stabilité de la protéine anti-apoptotique BCL2A1
Lionnard, L. (2018) · theses.fr (ABES) · doi:10.70675/1eec02ffz98dez4a56z98e2z389a2cd8558d
Impact of aging on cardiac mesenchymal stromal cells
Martini, H. (2019) · theses.fr (ABES) · doi:10.70675/bb7ddcb3z0b6az4c39za6eczc94e0563f0a3
Dissecting the impact of cellular senescence on muscle regeneration
Cazin, C. (2020) · theses.fr (ABES) · doi:10.70675/42a7ff38zb338z4eb8za925z2ce0a01ee74e
Senolytic and Senomorphic Compounds Derived from Food
Hayakawa, T., & Motoyama, N. (2026) · Springer eBooks · doi:10.1007/978-981-95-7068-3_65
Oliveira, M. L., Nuantang, K., Huré, G., Ávila-Ávila, A., Bresson, L., Haumont, S., Kostova, V., Novak, T., Toumelin-Braizat, G. L., Guerlesquin, J., et al. (2026) · Leukemia · doi:10.1038/s41375-026-02998-z
Tian, Z., Chatla, S., Indulkar, S., Kim, D., Wei, X., Liao, Y., Yang, D., Pompetti, A., Calendo, G., Wang, C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.25.734617
Self-citationSafety and Management of Targeted Therapies for Relapsed/Refractory Chronic Lymphocytic Leukemia
Ailawadhi, S., Omercikoglu, E., Paulus, A., Parrondo, R. D., & Chanan-Khan, A. A. (2026) · Drug Safety · doi:10.1007/s40264-026-01678-2
Wu, L., Budak, B., Ofogo, O., Jouneghani, A. J., JeanRichard, P., Bachmann, D., & Kaufmann, T. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01829-z
Huda, M. N., Afrin, H., Khatun, Z., An, J. M., Lee, Y.-K., & Nurunnabi, M. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.6c00017
BCLXL blockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancer
Venkatachalam, A., Strathman, A. R., Hou, X., Correia, C., Meng, X. W., McGehee, C. D., Balczewski, E. A., Duffield, L. N., Rossman, O. K., Wong, C., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02870-7
Current advances in drug discovery for aging
Rivero-Segura, N. A., Santiago-de-la-Cruz, J. A., Castillo-Vázquez, S. K., Rodriguez-Cuartas, J. D., Quiroz‐Baez, R., & Gómez-Verján, J. C. (2026) · Advances in biogerontology · doi:10.1016/bs.abger.2026.08.001
Whaley, M. G., Saraf, N., Chow, D., Riley, S. G., Vu, J. A., Bringhurst, M. F., Li, P., Bakri, S. J., & Haak, A. J. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.105045
BindingDB (2020) · UC San Diego · doi:10.7270/q2zk5k94
BindingDB (2022) · UC San Diego · doi:10.7270/q2542s8d
BindingDB Entry 50012486: Structure-Based Design of A-1293102, a Potent and Selective BCL-X
BindingDB (2022) · UC San Diego · doi:10.7270/q2r78jw5
BindingDB Entry 50009085: The chemical biology of apoptosis: Revisited after 17 years.
BindingDB (2021) · UC San Diego · doi:10.7270/q2r78jmk
BindingDB Entry 50015887: Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment.
BindingDB (2023) · UC San Diego · doi:10.7270/q2m049dt
Metadata
- Authors
- Leverson, J. D., Phillips, D. C., Mitten, M. J., Boghaert, E. R., Diaz, D., Tahir, S. K., Belmont, L. D., Nimmer, P., Xiao, Y., Ma, X. M., Lowes, K. N., Kovar, P., Chen, J., Jin, S., Smith, M., Xue, J., Zhang, H., Oleksijew, A., Magoc, T. J., Vaidya, K. S., Albert, D. H., Tarrant, J. M., La, N., Wang, L., Tao, Z.-F., Wendt, M. D., Sampath, D., Rosenberg, S. H., Tse, C., S. Huang, D. C., Fairbrother, W. J., Elmore, S. W., & Souers, A. J.
- Affiliations
- AbbVie (United States) (US)
- Genentech (US)
- AbbVie Inc., North Chicago, IL 60064, USA.
- The University of Melbourne (AU)
- Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
- Corresponding author
- Leverson, Joel D.
- Ma, Xiaoju Max
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2015-03-18
- Volume
- 7
- Issue
- 279
- Pages
- 279ra40-279ra40
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2110525250
- Cited by
- 541
- References
- 51
- Citations by year
- 2026: 22 · 2025: 33 · 2024: 34 · 2023: 38 · 2022: 58 · 2021: 56 · 2020: 69 · 2019: 49 · 2018: 58 · 2017: 65 · 2016: 43 · 2015: 12
- FWCI
- 25.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Leukemia and Lymphoma Society
- Medical Research Council (461219, 461221, 1016701)
- Australian Cancer Research Foundation
- Cancer Council Victoria
- Australian National Health
- Independent Research Institutes Infrastructure Support Scheme (361646)
- Victorian State Government Operational Infrastructure Support
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- BCL-2 inhibitor, venetoclax, navitoclax, BCL-XL inhibition, A-1331852, docetaxel combination, neutropenia, thrombocytopenia, granulopoiesis, solid tumors, chronic lymphocytic leukemia
- MeSH terms
- Docetaxel, Administration, Oral, Aniline Compounds, Animals, Antineoplastic Agents, Cell Survival, Granulocytes, Humans, Isoquinolines, Kinetics, Neoplasm Transplantation, Neoplasms, Neutropenia, Neutrophils, Sulfonamides, Thrombocytopenia, Gene Expression Regulation, Neoplastic, Bridged Bicyclo Compounds, Heterocyclic, Proto-Oncogene Proteins c-bcl-2, Gene Expression Profiling, Taxoids, Cell Line, Tumor, bcl-X Protein, Mice, Benzothiazoles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
